PARP Inhibitors | Community Health

PARP inhibitors are a class of pharmacological inhibitors that target the enzyme poly ADP ribose polymerase (PARP), which plays a crucial role in repairing DNA in damaged cells. These drugs have shown significant promise in the treatment of heritable cancers, including ovarian cancer, and are also being explored as potential treatments for acute life-threatening diseases such as stroke and myocardial infarction, as well as long-term neurodegenerative diseases. With several PARP inhibitors, including [[olaparib|Olaparib]] and [[rucaparib|Rucaparib]], already approved by the [[fda|FDA]] for the treatment of certain types of cancer, the field of PARP inhibition is rapidly evolving. According to a study published in the [[journal-of-clinical-oncology|Journal of Clinical Oncology]], PARP inhibitors have been shown to improve progression-free survival in women with recurrent platinum-sensitive ovarian cancer. As research continues to uncover the full potential of PARP inhibitors, they are likely to become an increasingly important part of the arsenal against cancer and other diseases. With the support of organizations such as the [[national-cancer-institute|National Cancer Institute]] and the [[american-cancer-society|American Cancer Society]], the development of PARP inhibitors is expected to continue to advance in the coming years.